Rizzieri, D. A., Koh, L. P., Long, G. D., Gasparetto, C., Vredenburgh, J. J., Buckley, P. J., … Chao, N. J. (2003). Clinical outcome and immune reconstitution following alemtuzumab T cell depleted nonmyeloablative allogeneic immunotherapy using HLA mis-matched (3-5/6) related hematopoietic stem cells. In BLOOD (Vol. 102, pp. 482A-482A). SAN DIEGO, CALIFORNIA: AMER SOC HEMATOLOGY.

Rizzieri, D. A., L. P. Koh, G. D. Long, C. Gasparetto, J. J. Vredenburgh, P. J. Buckley, G. Gong, et al. “Clinical outcome and immune reconstitution following alemtuzumab T cell depleted nonmyeloablative allogeneic immunotherapy using HLA mis-matched (3-5/6) related hematopoietic stem cells.” In BLOOD, 102:482A-482A. AMER SOC HEMATOLOGY, 2003.

Rizzieri DA, Koh LP, Long GD, Gasparetto C, Vredenburgh JJ, Buckley PJ, et al. Clinical outcome and immune reconstitution following alemtuzumab T cell depleted nonmyeloablative allogeneic immunotherapy using HLA mis-matched (3-5/6) related hematopoietic stem cells. In: BLOOD. AMER SOC HEMATOLOGY; 2003. p. 482A-482A.

Rizzieri, D. A., et al. “Clinical outcome and immune reconstitution following alemtuzumab T cell depleted nonmyeloablative allogeneic immunotherapy using HLA mis-matched (3-5/6) related hematopoietic stem cells.” BLOOD, vol. 102, no. 11, AMER SOC HEMATOLOGY, 2003, pp. 482A-482A.

Rizzieri DA, Koh LP, Long GD, Gasparetto C, Vredenburgh JJ, Buckley PJ, Gong G, Lagoo A, Davis P, Lassiter M, Rooney B, Niedzwiecki D, Waters-Pick B, Burleson J, Thompson M, Johns A, Folz RJ, Horwtiz ME, Sullivan K, Morris A, Chao NJ. Clinical outcome and immune reconstitution following alemtuzumab T cell depleted nonmyeloablative allogeneic immunotherapy using HLA mis-matched (3-5/6) related hematopoietic stem cells. BLOOD. AMER SOC HEMATOLOGY; 2003. p. 482A-482A.